Skip to content

Body composition in renal cell cancer: associations with survival outcomes, tumour characteristics, lifestyle habits, and circulating biomarkers

Body composition in renal cell cancer: associations with survival outcomes, tumour characteristics, lifestyle habits, and circulating biomarkers - ReLife

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42904
Enrollment
400
Registered
2017-03-02
Start date
2018-02-06
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney cancer renal cell cancer

Interventions

Biomarkers
Body composition
Lifestyle
Renal cell carcinoma

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Stage I-III RCC, diagnosed from 2017 - Aged between 18 and 75 years at diagnosis - Able to communicate in Dutch, to read and understand the patient information and informed consent form - Able to fill out questionnaires, and to visit the hospital to donate blood samples

Exclusion criteria

Exclusion criteria: Patients diagnosed with another type of cancer in the 5 years before RCC diagnosis

Design outcomes

Primary

MeasureTime frame
The main study endpoints are cross-sectional area and mean radiodensity of SM, VAT, and APF at baseline. The main study parameters are patient and tumour characteristics, dietary and physical activity habits, and circulating concentrations of biomarkers (in total 18 parameters, e.g. age, sex, tumour stage, and energy intake).

Secondary

MeasureTime frame
Secondary study endpoints are cross-sectional areas and mean radiodensity of SAT, IMAT, and TAT at baseline, cross-sectional areas and mean radiodensity of all body composition features at follow-up, and changes in cross-sectional areas and mean radiodensity of all body composition features per year. Secondary study parameters are other patient and tumour characteristics, dietary and physical activity habits, and circulating concentrations of biomarkers.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)